Protected graft copolymer (pgc) in imaging and therapy: A platform for the delivery of covalently and non-covalently bound drugs

Theranostics

Volumn 2, Issue 6, 2012, Pages 553-576

  Bogdanov, Alexei A ^a   Mazzanti, Mary ^a   Castillo, Gerardo ^b,c   Bolotin, Elijah ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b PharmaIN Corporation   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chelate; Contrast agent; Gadolinium; Gaft copolymer; Paramagnetic; Poly(ethylene glycol)

Indexed keywords

BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; CATHEPSIN B; CATHEPSIN K; COPOLYMER; CY5.5; CYSTEINE PROTEINASE; DEXTRAN; FLUORESCENT DYE; GADOLINIUM; GADOLINIUM PENTETATE; MACROGOL; MACROGOL DERIVATIVE; MATRIX METALLOPROTEINASE; METHOTREXATE; METHOXYPOLYETHYLENE GLYCOL SUCCINATE; PENTETATE TECHNETIUM TC 99M; PENTETIC ACID; POLYAMIDOAMINE; POLYAMINOACID; POLYLYSINE; POLYPEPTIDE; PROTECTED GRAFT COPOLYMER; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; SERUM ALBUMIN; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 PROTEIN TYROSINE KINASE INHIBITOR;

AQUEOUS SOLUTION; ARTHRITIS; ATHEROSCLEROSIS; BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD VOLUME; BREAST ADENOCARCINOMA; CHEMICAL BOND; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HYDRODYNAMICS; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POLYMERIZATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; TUMOR MICROENVIRONMENT;

EID: 84864413810     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4070     Document Type: Review

References (103)

1. Toncheva V, Wolfert MA, Dash PR, Oupicky D, Ulbrich K, Seymour LW, et al. Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers. Biochim Biophys Acta. 1998; 1380: 354-68.
2. Choi YH, Liu F, Kim JS, Choi YK, Park JS, Kim SW. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J Control Release. 1998; 54: 39-48.
3. Bogdanov A, Kayne L, Weissleder R. Graft copolymers as carriers for systemic delivery of expression vectors. In: Controlled Release Society I, editor. The 25th Int. Symp. Controlled Rel. Bioact. Mater. Las Vegas, NV: Controlled Release Society, Inc. 1998: 91-2.
4. Read ML, Dash PR, Clark A, Howard KA, Oupicky D, Toncheva V, et al. Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers. Eur J Pharm Sci. 2000; 10: 169-77.
5. Choi YR, Chae SY, Ahn CH, Lee M, Oh S, Byun Y, et al. Development of polymeric gene delivery carriers: PEGylated copolymers of L-lysine and L-phenylalanine. J Drug Target. 2007; 15: 391-8.
6. Bogdanov AJ, Tsai E, Bogdanova A, Papisov M, Brady T, Weissleder R. Novel agent for contrast-enhanced MR angiography and targeting. Radiology. 1992; 185: 128.
7. Xun W, Wang HY, Li ZY, Cheng SX, Zhang XZ, Zhuo RX. Self-assembled micelles of novel graft amphiphilic copolymers for drug controlled release. Colloids Surf B Biointerfaces. 2011; 85: 86-91.
8. Licciardi M, Cavallaro G, Di Stefano M, Pitarresi G, Fiorica C, Giammona G. New self-assembling polyaspartylhydrazide copolymer micelles for anticancer drug delivery. Int J Pharm. 2010; 396: 219-28.
9. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm. 2000; 50: 61-81.
10. Katchalski E, Sela M, Silman H, Berger A. Polyamino acids as protein models. In: Neurath H, editor. The Proteins. New York: Academic Press Inc. 1964: 405-581.
11. Nathan A, Zalipsky S, Ertel SI, Agathos SN, Yarmush ML, Kohn J. Copolymers of lysine and polyethylene glycol: a new family of functionalized drug carriers. Bioconj Chem. 1993; 4: 54-62.
12. Wolfert MA, Schacht EH, Toncheva V, Ulbrich K, Nazarova O, Seymour LW. Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. Human Gene Ther. 1996; 7: 2123-33.
13. Trubetskoy VS, Gazelle GS, Wolf GL, Torchilin VP. Block-copolymer of polyethylene glycol and polylysine as a carrier of organic iodine: design of long-circulating particulate contrast medium for X-ray computed tomography. J Drug Target. 1997; 4: 381-8.
14. Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J Control Release. 2009; 136: 14-20.
15. Chou PY, Scheraga HA. Calorimetric measurement of enthalpy change in the isothermal helix--coil transition of poly-L-lysine in aqueous solution. Biopolymers. 1971; 10: 657-80.
16. Bogdanov AJr, Weissleder R, Brady T. Protected angiopolymers and their use in blood pool imaging. In: VP T, editor. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL: CRC Press. 1995: 502-22.
17. Bogdanov A, Jr., Wright SC, Marecos EM, Bogdanova A, Martin C, Petherick P, et al. A long-circulating co-polymer in passive targeting to solid tumors. J Drug Target. 1997; 4: 321-30.
18. Bogdanov AA, Weissleder R, Frank HW, Bogdanova AV, Nossif N, Schaffer BK, et al. A New Macromolecule as a contrast agent for MR-angiography - preparation, properties, and animal studies. Radiology. 1993; 187: 701-6.
19. Castillo G, Reichstetter S, Bolotin E. Extending residence time and stability of peptides by Protected Graft Copolymer (PGC) excipient: GLP-1 example. Pharm Res. 2011; 29: 306-18.
20. Bogdanov AA, Lewin M, Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev. 1999; 37: 279-93.
21. Baxter AB, Melnikoff S, Stites DP, Brasch RC. AUR Memorial Award 1991. Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging. Induction and characterization of antibodies in animals. Invest Radiol. 1991; 26: 1035-40.
22. Smyth H, Carpenter C, Shaffer C. The toxicity of high molecular weight poly (ethylene glycols): chronic and parenteral administration. J Am Pharm Assoc. 1947; 36: 157-60.
23. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of poly(ethylene glycol). J Biol Chem. 1977; 252: 3578-81.
24. Nucci M, Schorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Delivery Revs. 1993; 6: 133-51.
25. Katre N. The conjugation of proteins with polyethylne glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv Drug Delivery Revs. 1993; 10: 91-114.
26. Bogdanov AJ, Weissleder R, Brady T. Long-circulating blood pool imaging agents. Adv Drug Delivery Revs. 1995; 16: 335-48.
27. Frank H, Weissleder R, Bogdanov AAJr., Brady TJ. Detection of pulmonary emboli by using MR angiography with MPEG-PL-GdDTPA: an experimental study in rabbits. Amer J Roentgenol. 1994; 162: 1041-6.
28. Gupta H, Weissleder R, Bogdanov AAJr., Brady TJ. Experimental gastrointestinal hemorrhage: detection with contrast-enhanced MR imaging and scintigraphy. Radiology. 1995; 196: 239-44.
29. Donahue KM, Weisskoff RM, Burstein D. Water diffusion and exchange as they influence contrast enhancement. J Magn Reson Imaging. 1997; 7: 102-10.
30. Kim YR, Savellano MD, Weissleder R, Bogdanov A, Jr. Steady-state and dynamic contrast MR imaging of human prostate cancer xenograft tumors: a comparative study. Technol Cancer Res Treat. 2002; 1: 489-95.
31. Donahue KM, Weisskoff RM, Chesler DA, Kwong KK, Bogdanov AAJr., Mandeville JB, et al. Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 1996; 36: 858-67.
32. Kim YR, Tejima E, Huang S, Atochin DN, Dai G, Lo EH, et al. In vivo quantification of transvascular water exchange during the acute phase of permanent stroke. Magn Reson Med. 2008; 60: 813-21.
33. Jiang Q, Ewing JR, Ding GL, Zhang L, Zhang ZG, Li L, et al. Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. J Cereb Blood Flow Metab. 2005; 25: 583-92.
34. Gotoh O, Asano T, Koide T, Takakura K. Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I: The time courses of the brain water, sodium and potassium contents and blood-brain barrier permeability to 125I-albumin. Stroke. 1985; 16: 101-9.
35. Zaharchuk G, Bogdanov AAJr., Marota JJ, Shimizu-Sasamata M, Weisskoff RM, Kwong KK, et al. Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): a steady-state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction. Magn Reson Med 1998; 40: 666-78.
36. Zaharchuk G, Mandeville JB, Bogdanov AAJr., Weissleder R, Rosen BR, Marota JJ. Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke. 1999; 30: 2197-204.
37. Bogdanov AAJr., Callahan RJ, Wilkinson RA, Martin C, Cameron JA, Fischman AJ, et al. Synthetic copolymer kit for radionuclide blood-pool imaging. J Nucl Med. 1994; 35: 1880-6.
38. Callahan RJ, Bogdanov A, Jr., Fischman AJ, Brady TJ, Weissleder R. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. Amer J Roentgenol. 1998; 171: 137-43.
39. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore D, et al. Tumor angiogenesis: a new significant andindependent prognostic indicator in early-stage breast carcinoma. Jour Natl Cancer Inst. 1992; 84: 1875-87.
40. Bogdanov AJr, Weissleder R, Tsai E, Schaffer B, Bogdanova A, Nossiff N, et al. Tumor neovascularity imaging by contrast-enhanced MR angiography. New York, NY: 12th Annual Scientific Meeting of the Society of Magnetic Resonance in Medicine. 1993:577.
41. Weissleder R, Cheng HC, Marecos E, Kwong K, Bogdanov A, Jr. Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer 1998; 34: 1448-54.
42. Kim YR, Savellano MD, Savellano DH, Weissleder R, Bogdanov A, Jr. Measurement of tumor interstitial volume fraction: method and implication for drug delivery. Magn Reson Med. 2004; 52: 485-94.
43. Lewin M, Bredow S, Sergeyev N, Marecos E, Bogdanov A, Jr., Weissleder R. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int J Cancer. 1999; 83: 798-802.
44. Kim YR, Yudina A, Figueiredo J, Reichardt W, Hu-Lowe D, Petrovsky A, et al. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res. 2005; 65: 9253-60.
45. Kim YR, Rebro KJ, Schmainda KM. Water exchange and inflow affect the accuracy of T1-GRE blood volume measurements: implications for the evaluation of tumor angiogenesis. Magn Reson Med. 2002; 47: 1110-20.
46. Bogdanov A, Jr., Marecos E, Cheng HC, Chandrasekaran L, Krutzsch HC, Roberts DD, et al. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study. Neoplasia. 1999; 1: 438-45.
47. Kang HW, Walvick R, Bogdanov A, Jr. In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells. FASEB J. 2009; 23: 4126-34.
48. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol. 1993; 9: 541-73.
49. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999; 17: 375-8.
50. Mahmood U, Tung CH, Bogdanov A, Jr., Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology. 1999; 213: 866-70.
51. Tung C, Mahmood U, Bredow S, Bogdanov A, Weissleder R. A cathepsin D sensitive near infrared fluorescence probe for in vivo imaging of enzyme activity. Bioconj Chem. 1999; 10: 892-6.
52. Marten K, Bremer C, Khazaie K, Sameni M, Sloane B, Tung CH, et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 2002; 122: 406-14.
53. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001; 7: 743-8.
54. Pham W, Choi Y, Weissleder R, Tung CH. Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconj. Chem. 2004; 15: 1403-7.
55. Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res. 2005; 65: 9398-405.
56. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem & Biol. 2004; 11: 99-106.
57. Hsiao JK, Law B, Weissleder R, Tung CH. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. J Biomed Opt 2006; 11: 34013.
58. Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia. 2004; 6: 95-105.
59. Bogdanov AJ, Lin C, Simonova M, Matuszewski L, Weissleder R. Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment. Neoplasia. 2002; 4: 228-36.
60. Bremer C, Tung CH, Bogdanov A, Jr., Weissleder R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology. 2002; 222: 814-8.
61. Gupta H, Wilkinson RA, Bogdanov AAJr., Callahan RJ, Weissleder R. Inflammation: imaging with methoxy poly(ethylene glycol)-poly-L-lysine-DTPA, a long-circulating graft copolymer. Radiology. 1995; 197: 665-9.
62. Medarova Z, Castillo G, Dai G, Bolotin E, Bogdanov A, Moore A. Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes. Diabetes 2007; 56: 2677-82.
63. Wunder A, Tung CH, Muller-Ladner U, Weissleder R, Mahmood U. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum. 2004; 50: 2459-65.
64. Lai WF, Chang CH, Tang Y, Bronson R, Tung CH. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthritis Cartilage. 2004; 12: 239-44.
65. Kozloff KM, Quinti L, Patntirapong S, Hauschka PV, Tung CH, Weissleder R, et al. Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone. 2009; 44: 190-8.
66. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002; 106: 2894-900.
67. Falk E. Why do plaques rupture? Circulation. 1992; 86: 11130-42.
68. Schroeder AP, Falk E. Pathophysiology and inflammatory aspects of plaque rupture. Cardiol Clin. 1996; 14: 211-20.
69. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002; 105: 2766-71.
70. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006; 114: 55-62.
71. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation. 2005; 111: 1800-5.
72. Matsumura Y, Oda T, Maeda H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Gan To Kagaku Ryoho. 1987; 14: 821-9.
73. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189-207.
74. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;: 3-53.
75. Marecos E, Weissleder R, Bogdanov A, Jr. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconj Chem. 1998; 9: 184-91.
76. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993; 261: 212-5.
77. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res. 2006; 66: 7225-9.
78. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA, Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA. 1987; 84: 9238-42.
79. Kang HW, Weissleder R, Bogdanov A, Jr. Targeting of MPEG-protected polyamino acid carrier to human E-selectin in vitro. Amino Acids. 2002; 23: 301-8.
80. Bogdanov AAJr., Martin C, Bogdanova AV, Brady TJ, Weissleder R. An adduct of cis-diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: synthesis and cytotoxic properties. Bioconjug Chem. 1996; 7: 144-9.
81. Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. [Review] [71 refs]. Biochimica et Biophysica Acta. 1985; 780: 167-80.
82. Sherman SE, Lippard SJ. Structural Aspects of Platinum Anticancer Drug Interactions with DNA. Cem Rev. 1987; 87: 1153-81.
83. Muggia FM, Rozencweig M, Penta J. Clinical implications of cisplatin pharmacology. Recent Results Cancer Res. 1980; 74: 132-8.
84. Reichstetter S, Castillo GM, Lai M, Nishimoto-Ashfield A, Banerjee A, Bogdanov A, et al. Protected Graft Copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus(R) (Insulin-Glargine): A streptozotocin-induced, diabetic sprague dawley rats study. Pharm Res. 2011; doi:10.1007/s11095-011-0646-8.
85. Torchilin V, Omelyanenko V, Papisov M, Bogdanov AJ, Trubetskoy V, Herron J, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochimi Biophys Acta. 1994; 1195: 11-20.
86. Reichstetter S, Castillo G, Perfetti R, Leahy M, Bolotin E. Long acting GLP-1 for the treatment of type 2 diabetes. Diabetes 2007; 56: A144-A.
87. Reichstetter S, Castillo G, Medarova Z, Moore A, Perfetti R, Leahy M, et al. Long acting GLP-1 for the treatment of type I diabetes. Diabetes 2007; 56: A73-A.
88. Castillo G, Reichstetter S, Medarova Z, Moore A, Bolotin E. PGC-GLP-1: Pharmacokinetics in rodents. Diabetes 2007; 56: A554-A.
89. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991; 252: 120-3.
90. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 1987; 326: 697-8.
91. Gambaryan S, Wagner C, Smolenski A, Walter U, Poller W, Haase W, et al. Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells. Proc Natl Acad Sci U S A. 1998; 95: 9003-8.
92. Cherradi N, Brandenburger Y, Rossier MF, Vallotton MB, Stocco DM, Capponi AM. Atrial natriuretic peptide inhibits calcium-induced steroidogenic acute regulatory protein gene transcription in adrenal glomerulosa cells. Mol Endocrinol. 1998; 12: 962-72.
93. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986; 324: 473-6.
94. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A. 1996; 93: 6215-9.
95. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008; 102: 185-92.
96. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995; 378: 65-8.
97. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997; 94: 14730-5.
98. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370: 1483-93.
99. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med. 1995; 1: 953-6.
100. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999; 282: 1568-75.
101. Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obes Rev. 2011; 12: e315-23.
102. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966; 50: 219-44.
103. Kim Y, Dai G, Bogdanov A, Rosen BR. Novel quantification method for measuring vessel size selective blood volume and transvascular water exchange rate: implication of visualizing neurovascular unit. ISMRM 13th scientific meeting Miami FL: ISMRM Berkeley; 2005.